

# **SAFETY DATA SHEET**

according to Regulation (EC) No. 1907/2006

Version 8.7 Revision Date 18.12.2024 Print Date 19.12.2024

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifiers

Product name : Trichloroacetic acid

Product Number : T4885

Brand : Sigma-Aldrich Index-No. : 607-004-00-7

REACH No. : 01-2119485186-30-XXXX

CAS-No. : 76-03-9

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, Manufacture of substances

1.3 Details of the supplier of the safety data sheet

Company : Merck Life Science UK Limited

New Road

The Old Brickyard GILLINGHAM

Dorset SP8 4XT

UNITED KINGDOM

Telephone : +44 (0)1747 833-000Fax : +44 (0)1747 833-313

E-mail address : TechnicalService@merckgroup.com

1.4 Emergency telephone

Emergency Phone # : +44 (0)870 8200418 (CHEMTREC)

#### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No 1272/2008 as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567

Skin corrosion, (Sub-category H314: Causes severe skin burns and eye

1A) damage.

Serious eye damage, (Category H318: Causes serious eye damage.

1)

Sigma-Aldrich- T4885

Short-term (acute) aquatic H400: Very toxic to aquatic life.

hazard, (Category 1)

Merck

Page 1 of 21

H410: Very toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

Labelling according Regulation (EC) No 1272/2008 as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567

Pictogram

Signal Word Danger

Hazard Statements

H314 Causes severe skin burns and eye damage. H410 Very toxic to aquatic life with long lasting effects.

**Precautionary Statements** 

P260 Do not breathe dust.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face

protection.

P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated

clothing. Rinse skin with water.

P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable

for breathing. Immediately call a POISON CENTER/ doctor.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes.

Remove contact lenses, if present and easy to do. Continue

rinsing.

Supplemental Hazard

Statements

none

#### Reduced Labeling (<= 125 ml)

Pictogram

Signal Word Danger

Hazard Statements

H314 Causes severe skin burns and eye damage.

**Precautionary Statements** 

P260 Do not breathe dust.

P280 Wear protective gloves/ protective clothing/ eye protection/ face

protection.

P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated

clothing. Rinse skin with water.

P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable

for breathing. Immediately call a POISON CENTER/ doctor.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes.

Remove contact lenses, if present and easy to do. Continue

rinsing.

Supplemental Hazard

Statements

none

# 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Sigma-Aldrich- T4885 Page 2 of 21

#### Ecological information:

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. Toxicological information:

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. Vesicant.

# **SECTION 3: Composition/information on ingredients**

#### 3.1 Substances

Synonyms : TCA

Component		Classification	Concentration
Trichloracetic acid			
CAS-No. EC-No. Index-No.	76-03-9 200-927-2 607-004-00-7	Skin Corr. 1A; Eye Dam. 1; Aquatic Acute 1; Aquatic Chronic 1; H314, H318, H400, H410 Concentration limits: >= 1 %: STOT SE 3, H335;	<= 100 %

For the full text of the H-Statements mentioned in this Section, see Section 16.

#### **SECTION 4: First aid measures**

#### 4.1 Description of first-aid measures

# **General advice**

First aiders need to protect themselves. Show this material safety data sheet to the doctor in attendance.

#### If inhaled

After inhalation: fresh air. Call in physician.

## In case of skin contact

In case of skin contact: Take off immediately all contaminated clothing. Rinse skin with water/ shower. Call a physician immediately.

# In case of eye contact

After eye contact: rinse out with plenty of water. Immediately call in ophthalmologist. Remove contact lenses.

#### If swallowed

After swallowing: make victim drink water (two glasses at most), avoid vomiting (risk of perforation). Call a physician immediately. Do not attempt to neutralise.

Merck

#### 4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

# 4.3 Indication of any immediate medical attention and special treatment needed

No data available

## **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

#### Suitable extinguishing media

Water Foam Carbon dioxide (CO2) Dry powder

#### Unsuitable extinguishing media

For this substance/mixture no limitations of extinguishing agents are given.

#### 5.2 Special hazards arising from the substance or mixture

Carbon oxides

Hydrogen chloride gas

Combustible.

Vapors are heavier than air and may spread along floors.

Forms explosive mixtures with air on intense heating.

Development of hazardous combustion gases or vapours possible in the event of fire.

#### 5.3 Advice for firefighters

Stay in danger area only with self-contained breathing apparatus. Prevent skin contact by keeping a safe distance or by wearing suitable protective clothing.

#### 5.4 Further information

Suppress (knock down) gases/vapors/mists with a water spray jet. Prevent fire extinguishing water from contaminating surface water or the ground water system.

# **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Advice for non-emergency personnel: Avoid inhalation of dusts. Avoid substance contact. Ensure adequate ventilation. Evacuate the danger area, observe emergency procedures, consult an expert.

For personal protection see section 8.

#### 6.2 Environmental precautions

Do not let product enter drains.

# 6.3 Methods and materials for containment and cleaning up

Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions (see sections 7 and 10). Take up dry. Dispose of properly. Clean up affected area. Avoid generation of dusts.

#### 6.4 Reference to other sections

For disposal see section 13.

# **SECTION 7: Handling and storage**

# **7.1** Precautions for safe handling

For precautions see section 2.2.

## 7.2 Conditions for safe storage, including any incompatibilities

Storage conditions

Merck

Page 4 of 21

Store under nitrogen. Tightly closed. Dry.

**Storage stability**Recommended storage temperature

2 - 8 °C

Storage class

Storage class (TRGS 510): 8B: Non-combustible, corrosive hazardous materials

#### 7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

# **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

## Ingredients with workplace control parameters

Contains no substances with occupational exposure limit values.

**Predicted No Effect Concentration (PNEC)** 

	(:::==)	
Compartment	Value	
Fresh water	0.00017 mg/l	
Sea water	0.000017 mg/l	
Aquatic intermittent release	0.0027 mg/l	
Fresh water sediment	0.00014 mg/kg	
Sea sediment	0.000014 mg/kg	
Soil	0.0046 mg/kg	
Sewage treatment plant	100 mg/l	

#### 8.2 Exposure controls

#### Personal protective equipment

#### **Eye/face protection**

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Tightly fitting safety goggles

#### Skin protection

This recommendation applies only to the product stated in the safety data sheet, supplied by us and for the designated use. When dissolving in or mixing with other substances and under conditions deviating from those stated in EN 16523-1 please contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, Internet: www.kcl.de).

Full contact Material: Viton®

Minimum layer thickness: 0.7 mm Break through time: 480 min Material tested: KCL 890 Vitoject®

This recommendation applies only to the product stated in the safety data sheet, supplied by us and for the designated use. When dissolving in or mixing with other substances and under conditions deviating from those stated in EN 16523-1 please contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell,

Internet: www.kcl.de).

Splash contact

Material: Nitrile rubber

Minimum layer thickness: 0.4 mm

Merck

Break through time: 30 min

Material tested: Camatril® (KCL 730 / Aldrich Z677442, Size M)

#### **Body Protection**

Acid-resistant protective clothing

# **Respiratory protection**

Recommended Filter type: Filter type B

The entrepeneur has to ensure that maintenance, cleaning and testing of respiratory protective devices are carried out according to the instructions of the producer. These measures have to be properly documented.

#### Control of environmental exposure

Do not let product enter drains.

# **SECTION 9: Physical and chemical properties**

# 9.1 Information on basic physical and chemical properties

a) Physical state Crystalline powder, Chunks

b) Color off-whitec) Odor stinging

d) Melting Melting point/ range: 54 - 58 °C - lit.

point/freezing point

e) Initial boiling point and boiling range

196 °C - lit.

f) Flammability (solid,

No data available

gas)

g) Upper/lower flammability or explosive limits

No data available

h) Flash point

> 113 °C - closed cup

i) Autoignition

temperature

does not ignite

j) Decomposition temperature

ion No data available

k) pH

1 at 81.7 g/l at 25 °C

Viscosity

Viscosity, kinematic: No data available Viscosity, dynamic: No data available

m) Water solubility

81.7 g/l at 20 °C - completely soluble

n) Partition coefficient:

log Pow: 1.33 - Bioaccumulation is not expected.

n-octanol/water

o) Vapor pressure 1 hPa at 51 °C

p) Density

1.62 g/cm3 at 25 °C - lit.

Relative density

No data available

q) Relative vapor

No data available

density

r) Particle

No data available



#### characteristics

s) Explosive properties Not classified as explosive.

t) Oxidizing properties none

# 9.2 Other safety information

Surface tension 27.8 mN/m at 80.2 °C

Relative vapor

density

5.64 - (Air = 1.0)

#### **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Forms explosive mixtures with air on intense heating.

A range from approx. 15 Kelvin below the flash point is to be rated as critical.

The following applies in general to flammable organic substances and mixtures: in correspondingly fine distribution, when whirled up a dust explosion potential may generally be assumed.

#### 10.2 Chemical stability

The product is chemically stable under standard ambient conditions (room temperature).

## 10.3 Possibility of hazardous reactions

Risk of explosion with:

silver salt

Exothermic reaction with:

alkalines

alkali hydroxides

Amines

Violent reactions possible with:

Strong oxidizing agents

sulfoxides

dimethyl sulfoxide

with

Copper

#### 10.4 Conditions to avoid

Exposure to moisture. Heat.

Strong heating.

## 10.5 Incompatible materials

No data available

#### 10.6 Hazardous decomposition products

In the event of fire: see section 5

# **SECTION 11: Toxicological information**

# 11.1 Information on toxicological effects

## **Acute toxicity**

LD50 Oral - Rat - 3,320 mg/kg

Remarks: (IUCLID)

Inhalation: No data available

Sigma-Aldrich- T4885 Page 7 of 21



Dermal: No data available

# Skin corrosion/irritation

Remarks: Causes severe burns.

Classified according to Regulation (EU) 1272/2008, Annex VI (Table 3.1/3.2)

# Serious eye damage/eye irritation

Remarks: Causes serious eye damage.

# Respiratory or skin sensitization

Maximization Test - Guinea pig

Result: negative

(OECD Test Guideline 406)

## Germ cell mutagenicity

In vivo tests did not show mutagenic effects

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Metabolic activation: with and without metabolic activation

Method: OECD Test Guideline 476

Result: Positive results were obtained in some in vitro tests.

Test Type: Chromosome aberration test in vitro

Test system: Human lymphocytes

Metabolic activation: with and without metabolic activation

Method: OECD Test Guideline 473

Result: positive

Test Type: In vivo micronucleus test

Species: Mouse

Cell type: Bone marrow

Application Route: Intraperitoneal Method: OECD Test Guideline 474

Result: negative

Carcinogenicity

No data available

#### Reproductive toxicity

No data available

#### Specific target organ toxicity - single exposure

No data available

# Specific target organ toxicity - repeated exposure

No data available

## **Aspiration hazard**

No data available

#### 11.2 Additional Information

#### **Endocrine disrupting properties**

#### **Product:**

Assessment The substance/mixture does not contain

components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

RTECS: AJ7875000

Sigma-Aldrich- T4885 Page 8 of 21

burning sensation, Cough, wheezing, laryngitis, Shortness of breath, spasm, inflammation and edema of the larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin., To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

# **SECTION 12: Ecological information**

## 12.1 Toxicity

No data available

# 12.2 Persistence and degradability

Biodegradability Result: 59 % - Not readily biodegradable.

Remarks: (External MSDS)

# 12.3 Bioaccumulative potential

No data available

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

# 12.6 Endocrine disrupting properties

# **Product:**

Assessment : The substance/mixture does not contain components

considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

#### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

#### **Product**

Waste material must be disposed of in accordance with the national and local regulations. Leave chemicals in original containers. No mixing with other waste. Handle uncleaned containers like the product itself. Notice Directive on waste 2008/98/EC.

#### **SECTION 14: Transport information**

14.1 UN number

ADR/RID: 1839 IMDG: 1839 IATA: 1839

Sigma-Aldrich- T4885 Page 9 of 21

#### 14.2 UN proper shipping name

ADR/RID: TRICHLOROACETIC ACID

IMDG: TRICHLOROACETIC ACID, SOLID

IATA: Trichloroacetic acid

# 14.3 Transport hazard class(es)

ADR/RID: 8 IMDG: 8 IATA: 8

14.4 Packaging group

ADR/RID: II IMDG: II IATA: II

14.5 Environmental hazards

ADR/RID: yes IMDG Marine pollutant: yes IATA: no

# 14.6 Special precautions for user

Tunnel restriction code : (E)

Further information : No data available

#### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006.

#### Authorisations and/or restrictions on use

#### **National legislation**

Seveso III: Directive 2012/18/EU of the E1 ENVIRONMENTAL HAZARDS European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

# Other regulations

Take note of Dir 94/33/EC on the protection of young people at work.

### 15.2 Chemical Safety Assessment

A Chemical Safety Assessment has been carried out for this substance.

#### SECTION 16: Other information

#### **Full text of H-Statements**

H314	Causes severe skin burns and eye	damage.
------	----------------------------------	---------

H318 Causes serious eye damage. H335 May cause respiratory irritation.

H400 Very toxic to aquatic life.



#### Full text of other abbreviations

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM -American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx -Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sigma-Aldrich- T4885

Canada

The information is believed to be correct but is not exhaustive and will be used solely as a guideline, which is based on current knowledge of the chemical substance or mixture and is applicable to appropriate safety precautions for the product. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.

The branding on the header and/or footer of this document may temporarily not visually match the product purchased as we transition our branding. However, all of the information in the document regarding the product remains unchanged and matches the product ordered. For further information please contact mlsbranding@sial.com.

Merck

Page 11 of 21

Sigma-Aldrich- T4885 Page 12 of 21



**Annex: Exposure scenario** 

#### Identified uses:

#### **Use: Industrial use**

**SU 3:** Industrial uses: Uses of substances as such or in preparations at industrial sites

**SU 3, SU9, SU 10:** Industrial uses: Uses of substances as such or in preparations at industrial sites, Manufacture of fine chemicals, Formulation [mixing] of preparations and/ or re-packaging (excluding alloys)

PC19: Intermediate

**PC21:** Laboratory chemicals

PROC1: Use in closed process, no likelihood of exposure

PROC2: Use in closed, continuous process with occasional controlled exposure

**PROC3:** Use in closed batch process (synthesis or formulation)

**PROC4:** Use in batch and other process (synthesis) where opportunity for exposure arises **PROC5:** Mixing or blending in batch processes for formulation of preparations and articles (multistage and/ or significant contact)

**PROC8a:** Transfer of substance or preparation (charging/ discharging) from/ to vessels/ large containers at non-dedicated facilities

**PROC8b:** Transfer of substance or preparation (charging/ discharging) from/ to vessels/ large containers at dedicated facilities

**PROC9:** Transfer of substance or preparation into small containers (dedicated filling line, including weighing)

**PROC10:** Roller application or brushing **PROC15:** Use as laboratory reagent

**ERC2, ERC4, ERC6a, ERC6b:** Formulation of preparations, Industrial use of processing aids in processes and products, not becoming part of articles, Industrial use resulting in manufacture of another substance (use of intermediates), Industrial use of reactive processing aids

#### **Use: Professional use**

**SU 22:** Professional uses: Public domain (administration, education, entertainment, services, craftsmen)

**SU 22:** Professional uses: Public domain (administration, education, entertainment, services, craftsmen)

**PC21:** Laboratory chemicals

**PROC15:** Use as laboratory reagent

**ERC2, ERC6a, ERC6b:** Formulation of preparations, Industrial use resulting in manufacture of another substance (use of intermediates), Industrial use of reactive processing aids

#### 1. Short title of Exposure Scenario: Industrial use

Main User Groups : SU 3

Sectors of end-use : **SU 3, SU9, SU 10**Chemical product category : **PC19, PC21** 

Process categories : PROC1, PROC2, PROC3, PROC4, PROC5, PROC8a,

PROC8b, PROC9, PROC10, PROC15

Environmental Release Categories : **ERC2**, **ERC4**, **ERC6a**, **ERC6b**:

Sigma-Aldrich- T4885 Page 13 of 21

#### 2. Exposure scenario

# 2.1 Contributing scenario controlling environmental exposure for: ERC2, ERC4, ERC6a, ERC6b

Daily amount per site (Msafe) : 87.3 kg

**Environment factors not influenced by risk management** 

Flow rate : 18,000 m3/d

Dilution Factor (River) : 10 Dilution Factor (Coastal Areas) : 100

Other given operational conditions affecting environmental exposure

Number of emission days per : 220

year

Emission or Release Factor: Air : 0 % Emission or Release Factor: : 0 %

Water

Emission or Release Factor: Soil : 0 %

Discharge into the environment must be avoided.

Technical conditions and measures / Organizational measures

Compartment : All compartments

Do not allow uncontrolled discharge of product into the environment.

Conditions and measures related to municipal sewage treatment plant

Type of Sewage Treatment Plant : Municipal sewage treatment plant

Flow rate of sewage treatment : 2,000 m3/d

plant effluent

Sludge Treatment : Sewage sludge should be incinerated.

# 2.2 Contributing scenario controlling worker exposure for: PROC1, PROC2, PROC3, PROC4, PROC9, PROC15

### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product

Mixture/Article up to 100 % (unless stated differently).

Physical Form (at time of use) : Solid, low dustiness

Process Temperature : < 78 °C

Frequency and duration of use

Frequency of use : 8 hours/day

Other operational conditions affecting workers exposure

Outdoor / Indoor : Indoor without local exhaust ventilation (LEV)

Organizational measures to prevent /limit releases, dispersion and exposure Covers daily exposures up to 8 hours.

Conditions and measures related to personal protection, hygiene and health evaluation

Wear chemically resistant gloves (tested to EN374) in combination with 'basic' employee training., Wear eye protection/ face protection., Wear suitable coveralls to prevent exposure to the skin.

# 2.3 Contributing scenario controlling worker exposure for: PROC5, PROC8a, PROC8b

#### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product

Mixture/Article up to 100 % (unless stated differently).

Physical Form (at time of use) : Solid, low dustiness

Process Temperature : < 78 °C

Sigma-Aldrich- T4885 Page 14 of 21

Frequency and duration of use

Frequency of use : 8 hours/day

Other operational conditions affecting workers exposure

Outdoor / Indoor : Indoor without local exhaust ventilation (LEV)

Organizational measures to prevent /limit releases, dispersion and exposure Covers daily exposures up to 8 hours.

# Conditions and measures related to personal protection, hygiene and health evaluation

Wear chemically resistant gloves (tested to EN374) in combination with specific activity training., Wear eye protection/ face protection., Wear suitable coveralls to prevent exposure to the skin.

# 2.4 Contributing scenario controlling worker exposure for: PROC10

### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product

Mixture/Article up to 100 % (unless stated differently).

Physical Form (at time of use) : Solid, low dustiness

Process Temperature : < 78 °C

Frequency and duration of use

Frequency of use : 8 hours/day

Other operational conditions affecting workers exposure

Outdoor / Indoor : Indoor without local exhaust ventilation (LEV)

Organizational measures to prevent /limit releases, dispersion and exposure Covers daily exposures up to 8 hours.

# Conditions and measures related to personal protection, hygiene and health evaluation

Wear chemically resistant gloves (tested to EN374) in combination with intensive management supervision controls., Wear eye protection/ face protection., Wear suitable coveralls to prevent exposure to the skin.

#### 3. Exposure estimation and reference to its source

## **Environment**

Contributin g Scenario	Exposure Assessment Method	Specific condition s	Compartme nt	Value	Level of Exposure	RCR*
ERC2	ECETOC TRA		Sea		87.3kg/day	< 1
			sediment			

#### Workers

Contributin g Scenario	Exposure Assessment Method	Specific conditions	Value	Level of Exposure	RCR*
PROC1	ECETOC TRA 3	acute, inhalative, systemic			< 0.01
PROC1	ECETOC TRA 3	acute, dermal, systemic			< 0.01
PROC1		acute,			< 0.01

Sigma-Aldrich- T4885 Page 15 of 21



		combined, systemic		
PROC1	ECETOC TRA 3	longterm,		< 0.01
		inhalative,		
		systemic		
PROC1	ECETOC TRA 3	longterm,		< 0.01
		dermal,		
		systemic		
PROC1		longterm,		< 0.01
		combined,		10.02
		systemic		
PROC2	ECETOC TRA 3	acute,		< 0.01
11002	202100 11013	inhalative,		10.01
		systemic		
PROC2	ECETOC TRA 3	acute, dermal,		0.10
TROCZ	LCLIOC IKA 3	systemic		0.10
PROC2		acute,		0.10
FROCZ		combined,		0.10
		systemic		
PROC2	ECETOC TRA 3			< 0.01
PROCZ	ECETOC TRA 3	longterm, inhalative,		< 0.01
		•		
DDOCO	ECETOC TRA 3	systemic		0.10
PROC2	ECETOC TRA 3	longterm,		0.10
		dermal,		
DD 0 63		systemic		0.10
PROC2		longterm,		0.10
		combined,		
		systemic		9.04
PROC3	ECETOC TRA 3	acute,		< 0.01
		inhalative,		
		systemic		0.05
PROC3	ECETOC TRA 3	acute, dermal,		0.05
		systemic		
PROC3		acute,		0.05
		combined,		
		systemic		
PROC3	ECETOC TRA 3	longterm,		< 0.01
		inhalative,		
		systemic		
PROC3	ECETOC TRA 3	longterm,		0.05
		dermal,		
		systemic		
PROC3		longterm,		0.05
		combined,		
		systemic		
PROC4	ECETOC TRA 3	acute,		0.02
		inhalative,		
		systemic		
PROC4	ECETOC TRA 3	acute, dermal,		0.49
		systemic		
PROC4		acute,		0.51
		combined,		
		systemic	<u>                                       </u>	
PROC4	ECETOC TRA 3	longterm,		< 0.01
		inhalative,		
		systemic		

Sigma-Aldrich- T4885 Page 16 of 21



PROC4   Systemic   O.49	PROC4	ECETOC TRA 3	longterm, dermal,		0.49
PROC9   ECETOC TRA 3   acute, inhalative, systemic	PPOC4	-	systemic		0.40
PROC9	PROC4				0.49
PROC9   ECETOC TRA 3   acute, dermal, systemic   Combined, systemic					
PROC9   ECETOC TRA 3   acute, dermal, systemic   acute, combined, systemic   PROC9   ECETOC TRA 3   longterm, inhalative, systemic   PROC15   ECETOC TRA 3   longterm, combined, systemic   PROC15   ECETOC TRA 3   acute, combined, systemic   PROC15   ECETOC TRA 3   acute, combined, systemic   PROC15   ECETOC TRA 3   acute, dermal, systemic   PROC15   ECETOC TRA 3   acute, dermal, systemic   PROC15   ECETOC TRA 3   acute, dermal, systemic   PROC15   ECETOC TRA 3   acute, combined, systemic   PROC15   ECETOC TRA 3   longterm, inhalative, systemic   PROC15   ECETOC TRA 3   longterm, dermal, systemic   PROC15   ECETOC TRA 3   longterm, dermal, systemic   PROC15   ECETOC TRA 3   longterm, dermal, systemic   PROC5   ECETOC TRA 3   acute, inhalative, systemic   PROC5   ECETOC TRA 3   acute, inhalative, systemic   PROC5   ECETOC TRA 3   acute, inhalative, systemic   PROC5   ECETOC TRA 3   acute, dermal, systemic   PROC5   ECETOC TRA 3   acute, dermal, systemic   PROC5   ECETOC TRA 3   acute, dermal, systemic   PROC5   ECETOC TRA 3   longterm, inhalative, systemic   PROC5   ECETOC TRA 3	PROC9	ECETOC TRA 3			< 0.01
PROC9         ECETOC TRA 3 acute, dermal, systemic         0.49           PROC9         acute, combined, systemic         0.49           PROC9         ECETOC TRA 3 longterm, inhalative, systemic         < 0.01					
PROC9	DD 0 00	ECETOC TDA 3			0.40
PROC9	PROC9	ECETOC TRA 3			0.49
PROC9 ECETOC TRA 3 longterm, inhalative, systemic  PROC9 ECETOC TRA 3 longterm, inhalative, systemic  PROC9 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 acute, enhalative, systemic  PROC15 ECETOC TRA 3 acute, dermal, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, longterm, systemic  PROC5 ECETOC TRA 3 longterm, longterm, systemic  PROC5 ECETOC TRA 3 longterm,	PROC9				0.49
PROC9   ECETOC TRA 3   Iongterm, inhalative, systemic	TROCS				0.15
PROC9 ECETOC TRA 3 longterm, inhalative, systemic  PROC9 ECETOC TRA 3 longterm, dermal, systemic  PROC9 longterm, combined, systemic  PROC15 ECETOC TRA 3 acute, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, combined, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 longterm, combined, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic					
PROC9	PROC9	ECETOC TRA 3			< 0.01
PROC9					
PROC9   Combined   Comparison   Combined   Comparison   Combined   Comparison   Combined   Comparison   Combined   Comparison   Compa					
PROC9   Iongterm, combined, systemic	PROC9	ECETOC TRA 3			0.49
PROC15 ECETOC TRA 3 acute, inhalative, systemic  PROC15 ECETOC TRA 3 acute, inhalative, systemic  PROC15 ECETOC TRA 3 acute, dermal, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 longterm, combined, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 longterm, combined, systemic  PROC15 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic			-		
PROC15 ECETOC TRA 3 acute, inhalative, systemic  PROC15 ECETOC TRA 3 acute, dermal, systemic  PROC15 ECETOC TRA 3 acute, dermal, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 longterm, combined, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic	DROCO				0.40
PROC15 ECETOC TRA 3 acute, inhalative, systemic  PROC15 ECETOC TRA 3 acute, dermal, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 longterm, combined, systemic  PROC15 longterm, combined, systemic  PROC16 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, longterm, longterm, systemic  PROC5 ECETOC TRA 3 longterm, longterm, longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, longterm, longterm, longterm, longterm, longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic	PROCS				0.49
PROC15 ECETOC TRA 3 acute, inhalative, systemic  PROC15 ECETOC TRA 3 acute, dermal, systemic  PROC15 CECTOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 CECTOC TRA 3 longterm, dermal, systemic  PROC15 CECTOC TRA 3 longterm, combined, systemic  PROC15 CECTOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 CECTOC TRA 3 longterm, combined, systemic  PROC5 CECTOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic			-		
inhalative, systemic  PROC15   ECETOC TRA 3   acute, dermal, systemic  PROC15   acute, combined, systemic  PROC15   ECETOC TRA 3   longterm, inhalative, systemic  PROC15   ECETOC TRA 3   longterm, dermal, systemic  PROC15   ECETOC TRA 3   longterm, combined, systemic  PROC15   longterm, combined, systemic  PROC5   ECETOC TRA 3   acute, inhalative, systemic  PROC5   ECETOC TRA 3   acute, inhalative, systemic  PROC5   ECETOC TRA 3   acute, combined, systemic  PROC5   ECETOC TRA 3   acute, combined, systemic  PROC5   ECETOC TRA 3   longterm, combined, systemic  PROC5   ECETOC TRA 3   longterm, inhalative, systemic  PROC5   ECETOC TRA 3   longterm, inhalative, systemic  PROC5   ECETOC TRA 3   longterm, dermal, systemic  PROC5   ECETOC TRA 3   longterm, dermal, systemic	PROC15	ECETOC TRA 3			< 0.01
PROC15 ECETOC TRA 3 acute, dermal, systemic  PROC15 acute, combined, systemic  PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 longterm, combined, systemic  PROC15 longterm, combined, systemic  PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic					
PROC15   Systemic   Combined,			systemic		
PROC15   acute, combined, systemic   0.03    PROC15   ECETOC TRA 3   longterm, inhalative, systemic   0.02    PROC15   ECETOC TRA 3   longterm, dermal, systemic   0.03    PROC15   CETOC TRA 3   longterm, combined, systemic   0.03    *Risk characterisation ratio   PROC5   ECETOC TRA 3   acute, inhalative, systemic   0.02    PROC5   ECETOC TRA 3   acute, dermal, systemic   0.49   0.51    PROC5   ECETOC TRA 3   longterm, inhalative, systemic   0.01    PROC5   ECETOC TRA 3   longterm, inhalative, systemic   0.49    PROC5   ECETOC TRA 3   longterm, inhalative, systemic   0.49    PROC5   ECETOC TRA 3   longterm, inhalative, systemic   0.49    PROC5   ECETOC TRA 3   longterm, dermal, systemic   0.49	PROC15	ECETOC TRA 3			0.02
Combined, systemic   PROC15   ECETOC TRA 3   longterm, inhalative, systemic					
PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 longterm, combined, systemic  *Risk characterisation ratio PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic	PROC15		-		0.03
PROC15 ECETOC TRA 3 longterm, inhalative, systemic  PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 longterm, combined, systemic  *Risk characterisation ratio PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 ECETOC TRA 3 longterm, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic			-		
inhalative, systemic  PROC15	PROC15	ECETOC TRA 3			< 0.01
PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 longterm, combined, systemic  *Risk characterisation ratio PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 acute, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic	TROCIS	LCLIOC IKA 3			< 0.01
PROC15 ECETOC TRA 3 longterm, dermal, systemic  PROC15 longterm, combined, systemic  *Risk characterisation ratio PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic			·		
PROC15   longterm, combined, systemic    *Risk characterisation ratio PROC5   ECETOC TRA 3   acute, inhalative, systemic    PROC5   ECETOC TRA 3   acute, dermal, systemic    PROC5   acute, combined, systemic    PROC5   ECETOC TRA 3   longterm, inhalative, systemic    PROC5   ECETOC TRA 3   longterm, inhalative, systemic    PROC5   ECETOC TRA 3   longterm, dermal, systemic    PROC5   ECETOC TRA 3   lo	PROC15	ECETOC TRA 3			0.02
PROC15   longterm, combined, systemic    *Risk characterisation ratio PROC5   ECETOC TRA 3   acute, inhalative, systemic    PROC5   ECETOC TRA 3   acute, dermal, systemic    PROC5   acute, combined, systemic    PROC5   ECETOC TRA 3   longterm, inhalative, systemic    PROC5   ECETOC TRA 3   longterm, inhalative, systemic    PROC5   ECETOC TRA 3   longterm, dermal, systemic    PROC5   ECETOC TRA 3   lo			dermal,		
*Risk characterisation ratio PROC5					
*Risk characterisation ratio PROC5	PROC15				0.03
*Risk characterisation ratio  PROC5   ECETOC TRA 3   acute, inhalative, systemic  PROC5   ECETOC TRA 3   acute, dermal, systemic  PROC5   acute, combined, systemic  PROC5   ECETOC TRA 3   longterm, inhalative, systemic  PROC5   ECETOC TRA 3   longterm, dermal, systemic  PROC5   ECETOC TRA 3   longterm, dermal, systemic					
PROC5 ECETOC TRA 3 acute, inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 acute, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic	*Diels charge	torication ratio	systemic		
inhalative, systemic  PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 acute, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  O.49  O.49			acute	I I	0.02
PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 acute, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic	FROCS	LCLIOC IRA 3	•		0.02
PROC5 ECETOC TRA 3 acute, dermal, systemic  PROC5 acute, combined, systemic  PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  O.49  O.49  O.49					
PROC5  PROC5  Combined, Systemic  PROC5  ECETOC TRA 3  Combined, Systemic  PROC5  ECETOC TRA 3  Combined, Systemic  Combined,	PROC5	ECETOC TRA 3			0.49
PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic					
PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic    O.49	PROC5				0.51
PROC5 ECETOC TRA 3 longterm, inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  O.49			· ·		
inhalative, systemic  PROC5 ECETOC TRA 3 longterm, dermal, systemic  0.49	22.005				
PROC5 ECETOC TRA 3 longterm, dermal, systemic 0.49	PROC5	ECETOC TRA 3			< 0.01
PROC5 ECETOC TRA 3 longterm, dermal, systemic 0.49					
dermal, systemic	PROC5	ECETOC TRA 3			0.49
systemic	FROCS	LCLIOC INA 3			0.43
			-		
	PROC5				0.49

Sigma-Aldrich- T4885 Page 17 of 21



		combined, systemic		
PROC8a	ECETOC TRA 3	acute,		0.02
		inhalative,		
		systemic		
PROC8a	ECETOC TRA 3	acute, dermal,		0.49
DD 0 60		systemic		0.51
PROC8a		acute,		0.51
		combined, systemic		
PROC8a	ECETOC TRA 3	longterm,		< 0.01
TROCOG	LCLIOC INA 3	inhalative,		V 0.01
		systemic		
PROC8a	ECETOC TRA 3	longterm,		0.49
		dermal,		
		systemic		
PROC8a		longterm,		0.49
		combined,		
		systemic		
PROC8b	ECETOC TRA 3	acute,		< 0.01
		inhalative,		
DD COL	ECETOC TRA 3	systemic		0.40
PROC8b	ECETOC TRA 3	acute, dermal,		0.49
PROC8b		systemic acute,		0.49
PROCOD		combined,		0.49
		systemic		
PROC8b	ECETOC TRA 3	longterm,		< 0.01
1110000	20210011010	inhalative,		0.01
		systemic		
PROC8b	ECETOC TRA 3	longterm,		0.49
		dermal,		
		systemic		
PROC8b		longterm,		0.49
		combined,		
*D:		systemic		
i .	terisation ratio	a auta	I I	1 0.02
PROC10	ECETOC TRA 3	acute, inhalative,		0.02
		systemic		
PROC10	ECETOC TRA 3	acute, dermal,		0.39
TROCIO	LCLIOC IIIA 3	systemic		0.55
PROC10		acute,		0.41
		combined,		
		systemic		
PROC10	ECETOC TRA 3	longterm,		< 0.01
		inhalative,		
	1	systemic		
PROC10	ECETOC TRA 3	longterm,		0.39
		dermal,		
DDCC10	+	systemic		0.40
PROC10		longterm, combined,		0.40
		systemic		
*D:-1:-1	l terisation ratio	Systemic		

<sup>\*</sup>Risk characterisation ratio

Sigma-Aldrich- T4885 Page 18 of 21



# 4. Guidance to Downstream User to evaluate whether he works inside the boundaries set by the Exposure Scenario

For scaling of worker exposure assessments performed with ECETOC TRA, please consult the Merck tool ScIDeEx® at www.merckmillipore.com/scideex.

Please refer to the following documents: ECHA Guidance on information requirements and chemical safety assessment Chapter R.12: Use descriptor system; ECHA Guidance for downstream users; ECHA Guidance on information requirements and chemical safety assessment Part D: Exposure Scenario Building, Part E: Risk Characterisation and Part G: Extending the SDS; VCI/Cefic REACH Practical Guides on Exposure Assessment and Communications in the Supply Chain; CEFIC Guidance Specific Environmental Release Categories (SPERCs).

## 1. Short title of Exposure Scenario: Professional use

Main User Groups : SU 22
Sectors of end-use : SU 22
Chemical product category : PC21
Process categories : PROC15

Environmental Release Categories : ERC2, ERC6a, ERC6b:

#### 2. Exposure scenario

# 2.1 Contributing scenario controlling environmental exposure for: ERC2, ERC6a, ERC6b

Daily amount per site (Msafe) : 87.3 kg

**Environment factors not influenced by risk management** 

Flow rate : 18,000 m3/d

Dilution Factor (River) : 10 Dilution Factor (Coastal Areas) : 100

Other given operational conditions affecting environmental exposure

Number of emission days per : 220

year

Emission or Release Factor: Air : 0 % Emission or Release Factor: : 0 %

Water

Emission or Release Factor: Soil : 0 %

Discharge into the environment must be avoided.

Technical conditions and measures / Organizational measures

Compartment : All compartments

Do not allow uncontrolled discharge of product into the environment.

Conditions and measures related to municipal sewage treatment plant

Type of Sewage Treatment Plant : Municipal sewage treatment plant

Flow rate of sewage treatment : 2,000 m3/d

plant effluent

Sludge Treatment : Sewage sludge should be incinerated.

2.2 Contributing scenario controlling worker exposure for: PROC15

Sigma-Aldrich- T4885 Page 19 of 21

#### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product

up to 100 % (unless stated differently). Mixture/Article

Physical Form (at time of use) : Solid, low dustiness

: < 78 °C Process Temperature

#### Frequency and duration of use

Frequency of use : 8 hours/day

# Other operational conditions affecting workers exposure

Outdoor / Indoor : Indoor without local exhaust ventilation (LEV)

Organizational measures to prevent /limit releases, dispersion and exposure Covers daily exposures up to 8 hours.

## Conditions and measures related to personal protection, hygiene and health evaluation

Wear chemically resistant gloves (tested to EN374) in combination with 'basic' employee training., Wear eye protection/ face protection., Wear suitable coveralls to prevent exposure to the skin.

#### 3. Exposure estimation and reference to its source

#### **Environment**

Contributin g Scenario	Exposure Assessment Method	Specific condition s	Compartme nt	Value	Level of Exposure	RCR*
ERC2	ECETOC TRA		Sea		87.3kg/day	< 1
			sediment			

#### Workers

Contributin g Scenario	Exposure Assessment Method	Specific conditions	Value	Level of Exposure	RCR*
PROC15	ECETOC TRA 3	acute, inhalative, systemic			< 0.01
PROC15	ECETOC TRA 3	acute, dermal, systemic			0.02
PROC15		acute, combined, systemic			0.03
PROC15	ECETOC TRA 3	longterm, inhalative, systemic			< 0.01
PROC15	ECETOC TRA 3	longterm, dermal, systemic			0.02
PROC15		longterm, combined, systemic			0.03

<sup>\*</sup>Risk characterisation ratio

# 4. Guidance to Downstream User to evaluate whether he works inside the boundaries set by the Exposure Scenario

Sigma-Aldrich- T4885 Page 20 of 21



For scaling of worker exposure assessments performed with ECETOC TRA, please consult the Merck tool ScIDeEx® at www.merckmillipore.com/scideex.

Please refer to the following documents: ECHA Guidance on information requirements and chemical safety assessment Chapter R.12: Use descriptor system; ECHA Guidance for downstream users; ECHA Guidance on information requirements and chemical safety assessment Part D: Exposure Scenario Building, Part E: Risk Characterisation and Part G: Extending the SDS; VCI/Cefic REACH Practical Guides on Exposure Assessment and Communications in the Supply Chain; CEFIC Guidance Specific Environmental Release Categories (SPERCs).

Sigma-Aldrich- T4885 Page 21 of 21

